+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sexually Transmitted Infection Diagnostics Kit Market by Infection Type, Technology, Sample Type, End User, Distribution Channel, Application - Global Forecast to 2030- Product Image
Sexually Transmitted Infection Diagnostics Kit Market by Infection Type, Technology, Sample Type, End User, Distribution Channel, Application - Global Forecast to 2030- Product Image
Sale

Sexually Transmitted Infection Diagnostics Kit Market by Infection Type, Technology, Sample Type, End User, Distribution Channel, Application - Global Forecast to 2030

  • PDF Icon

    Report

  • 184 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6081398
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Setting the Stage for Next-Generation STI Diagnostics

The landscape of sexually transmitted infection diagnostics has undergone rapid transformation in recent years, driven by a confluence of epidemiological pressures, technological breakthroughs, and evolving healthcare delivery models. Rising incidence rates of Chlamydia, Gonorrhea, HIV, and Syphilis have intensified the need for more accurate, rapid, and accessible diagnostic solutions. At the same time, patient expectations for privacy, convenience, and immediacy are reshaping the way tests are developed, distributed, and administered.

Against this backdrop, diagnostic manufacturers and healthcare providers must navigate complex regulatory frameworks and adapt to shifting payer requirements while harnessing the potential of novel technologies. Molecular techniques promise unparalleled sensitivity, immunoassays are increasingly automated and multiplexed, and rapid tests are pushing the boundaries of point-of-care convenience. This report delves into the critical forces redefining the STI diagnostics market, offering strategic insights that empower stakeholders to capitalize on emerging opportunities and mitigate key challenges.

Disruptive Trends Redefining Diagnostic Paradigms

The STI diagnostics ecosystem is undergoing disruptive shifts that are redefining conventional testing paradigms. Advances in microfluidics are enabling high-throughput multiplex assays on compact platforms, while digital connectivity is streamlining data reporting and remote patient monitoring. Moreover, point-of-care solutions are gaining traction as they bring testing closer to the patient, reducing turnaround time and improving linkage to treatment.

Simultaneously, the integration of artificial intelligence into image-based analysis and result interpretation is enhancing diagnostic accuracy and reducing operator dependence. Molecular methods have evolved from single-analyte PCR toward isothermal amplification techniques that operate without thermal cyclers, extending testing capabilities to resource-limited settings. In parallel, immunoassays are becoming more versatile, combining CLIA-level sensitivity with the simplicity of lateral flow formats. These transformative developments are converging to create a new generation of STI diagnostics that promise faster, more reliable results and a seamless patient experience.

Implications of 2025 U.S. Tariff Adjustments on Diagnostic Supplies

The implementation of new United States tariffs in 2025 has had a cascading effect on the supply chain for diagnostic reagents, instruments, and consumables. Many key components, including specialized enzymes, fluorescent dyes, and microfluidic cartridges, are sourced internationally and are now subject to increased import duties. Consequently, production costs have risen, prompting manufacturers to reassess pricing strategies and supply agreements.

In response, industry leaders are exploring alternative sourcing strategies, such as near-shoring critical raw materials or qualifying domestic suppliers to mitigate exposure to tariff volatility. Some companies are absorbing the incremental costs to preserve market share, whereas others are renegotiating distribution contracts to allocate expenses across the value chain. The net effect is a heightened imperative to optimize manufacturing efficiency, streamline logistics, and accelerate automation investments. As a result, organizations that proactively adapt to these tariff-driven dynamics can turn regulatory headwinds into opportunities for cost leadership and operational resilience.

Deep Dive into Market Segmentation Dynamics

A nuanced understanding of market segmentation reveals distinct growth trajectories and competitive dynamics across multiple dimensions. When considering infection type, Chlamydia and Gonorrhea tests account for a significant share of demand due to their high incidence and established screening protocols, while HIV and Syphilis diagnostics command specialist receptor networks and dedicated follow-up pathways. Technological segmentation underscores the dominance of immunoassays, where CLIA, ELISA, and Rapid Immunoassay formats coexist to balance sensitivity, throughput, and convenience. However, molecular approaches are rapidly gaining ground, with PCR subdivisions such as Multiplex PCR and Real Time PCR enabling simultaneous detection of multiple pathogens, and isothermal amplification methods like LAMP and RPA offering simplified workflows for decentralized settings. Rapid Test platforms including Dipstick and Lateral Flow Assay remain critical for immediate, point-of-care screening.

Sample type plays a pivotal role in adoption patterns. Serum and whole blood matrices cater to established laboratory workflows, whereas swab collections-spanning endocervical, rectal, urethral, and vaginal swabs-drive uptake in outpatient clinics and community testing events. First catch urine and midstream urine methodologies further expand non-invasive screening capabilities. End users vary from clinics and diagnostic laboratories to hospitals and research institutes, each with distinct procurement processes and quality requirements. Distribution channels range from direct tenders and hospital pharmacies to online sales platforms and retail pharmacies, reflecting a shift toward consumer-centric access models. Finally, applications in confirmation, monitoring, and screening each impose unique performance criteria, influencing product design and market positioning. Together, these segmentation insights provide a strategic blueprint for resource allocation, product development, and go-to-market strategies.

Regional Market Nuances Shaping Global Strategies

Regional markets each present unique opportunities and challenges shaped by epidemiology, infrastructure, and regulatory environments. In the Americas, robust healthcare networks and established reimbursement frameworks support advanced molecular and immunoassay platforms. The region’s high incidence rates for key infections drive routine screening programs, and sustained investments in public health initiatives underpin widespread adoption.

In Europe, Middle East & Africa, heterogeneous regulatory pathways and varying levels of healthcare access create a complex operating environment. While Western European nations maintain rigorous approval processes and high laboratory automation, emerging markets in the Middle East and Africa are embracing point-of-care and rapid test solutions to address resource constraints. Procurement through public tenders remains prevalent, shaping competitive dynamics and price sensitivity.

Asia-Pacific is characterized by rapid industrial expansion, government-led screening campaigns, and growing local manufacturing capacity. Price-sensitive markets are increasingly turning to cost-effective rapid tests and isothermal amplification assays, while tier-one economies invest heavily in next-generation molecular diagnostics. Strategic partnerships between global players and regional stakeholders are accelerating technology transfer and infrastructure development across the continent.

Competitive Landscape and Leading Innovators

The competitive landscape in STI diagnostics is defined by a blend of established conglomerates and agile specialists. Leading companies are differentiating through portfolio breadth, covering flow cytometry, immunoassays, molecular assays, and rapid tests. Strategic partnerships and acquisitions are driving consolidation, enabling integrated platforms that facilitate multiplex testing and data analytics.

Key players are investing heavily in research and development to enhance assay sensitivity, reduce time to result, and simplify instrument footprints. Connectivity features such as laboratory information system integration and cloud-based reporting are emerging as critical differentiators. Some firms are expanding their footprint through targeted collaborations with academic centers and public health agencies to validate novel biomarkers and streamline regulatory pathways. Others are bolstering their geographic reach by partnering with local distributors and contract manufacturers to optimize cost structures and accelerate market entry.

As price competition intensifies, companies are placing greater emphasis on service contracts, consumable revenue models, and bundled offerings that combine hardware, software, and assay consumables into comprehensive diagnostic solutions. This shift toward solution selling positions organizations to capture long-term customer value and foster deeper clinical partnerships.

Strategic Imperatives for Industry Leaders to Stay Ahead

To thrive in this rapidly evolving arena, industry leaders must adopt a multifaceted strategy that balances innovation with operational excellence. First, diversifying supplier networks and near-shoring critical component production can mitigate the impact of import tariffs and geopolitical disruption. Second, investing in modular, scalable manufacturing platforms-capable of producing immunoassays, molecular kits, and rapid tests on demand-will enhance responsiveness to market fluctuations.

In parallel, organizations should accelerate the development of multiplex assays that address co-infection profiles and leverage digital connectivity to deliver results directly into electronic health records. Cultivating partnerships with public health agencies and non-governmental organizations will broaden market access, particularly in underserved regions. Engaging payers early in the product lifecycle to secure reimbursement pathways for novel diagnostic modalities will further de-risk commercialization.

Finally, embedding agile project management methodologies and cross-functional innovation teams will foster a culture of continuous improvement, enabling rapid iteration on product design and go-to-market tactics. By aligning R&D, operations, and commercial functions around clearly defined performance metrics, companies can sustain growth and maintain leadership in an increasingly competitive landscape.

Rigorous Approach Underpinning Our Research Insights

Our research methodology integrates a rigorous blend of primary and secondary sources to ensure comprehensive and reliable insights. We conducted in-depth interviews with key opinion leaders, diagnostic developers, laboratory directors, and public health officials to capture firsthand perspectives on technological adoption, regulatory hurdles, and unmet clinical needs. Secondary research encompassed an extensive review of peer-reviewed journals, regulatory filings, patent databases, and corporate disclosures to map the competitive landscape and innovation trajectories.

Quantitative analysis involved the systematic compilation and triangulation of data from proprietary databases, financial reports, and import-export records to identify prevailing trends in reagent supply chains, pricing dynamics, and reimbursement policies. Qualitative analysis focused on thematic coding of expert interviews and case studies to elucidate best practices in assay design, manufacturing optimization, and market entry strategies. All findings underwent a rigorous validation process, including peer review by subject-matter experts, to ensure accuracy and relevance. The result is a robust, evidence-based foundation that supports actionable recommendations and strategic roadmaps for stakeholders across the STI diagnostics ecosystem.

Synthesis of Strategic Insights for Stakeholder Engagement

The synthesis of strategic insights presented herein equips stakeholders with a clear understanding of the forces shaping the STI diagnostics market. From tariff-driven cost pressures to the rapid ascent of decentralized testing modalities, this analysis highlights the critical intersections of technology, regulation, and market dynamics. By aligning product portfolios with evolving customer needs-whether in high-throughput laboratories, point-of-care settings, or community screening programs-organizations can capture new growth pathways while fortifying their competitive positioning.

Looking ahead, the ability to adapt supply chains, accelerate innovation cycles, and forge collaborative partnerships will distinguish market leaders from followers. As diagnostic platforms converge with digital health ecosystems, opportunities will emerge to deliver integrated care solutions that extend beyond mere testing. In this complex environment, stakeholders that proactively harness the insights and recommendations outlined in this report will be best positioned to deliver value to patients, providers, and payers alike.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Infection Type
    • Chlamydia
    • Gonorrhea
    • HIV
    • Syphilis
  • Technology
    • Flow Cytometry
    • Immunoassay
      • CLIA
      • ELISA
      • Rapid Immunoassay
    • Molecular
      • Isothermal Amplification
        • LAMP
        • RPA
      • PCR
        • Multiplex PCR
        • Real Time PCR
    • Rapid Test
      • Dipstick
      • Lateral Flow Assay
  • Sample Type
    • Blood
      • Serum
      • Whole Blood
    • Swab
      • Endocervical Swab
      • Rectal Swab
      • Urethral Swab
      • Vaginal Swab
    • Urine
      • First Catch Urine
      • Midstream Urine
  • End User
    • Clinics
    • Diagnostic Laboratories
    • Hospitals
    • Research Institutes
  • Distribution Channel
    • Direct Tender
    • Hospital Pharmacy
    • Online Sales
    • Retail Pharmacy
  • Application
    • Confirmation
    • Monitoring
    • Screening
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • F. Hoffmann-La Roche Ltd.
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Hologic, Inc.
  • Danaher Corporation
  • Thermo Fisher Scientific, Inc.
  • bioMérieux SA
  • Siemens Healthineers AG
  • Quidel Corporation
  • QIAGEN N.V.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Sexually Transmitted Infection Diagnostics Kit Market, by Infection Type
8.1. Introduction
8.2. Chlamydia
8.3. Gonorrhea
8.4. HIV
8.5. Syphilis
9. Sexually Transmitted Infection Diagnostics Kit Market, by Technology
9.1. Introduction
9.2. Flow Cytometry
9.3. Immunoassay
9.3.1. CLIA
9.3.2. ELISA
9.3.3. Rapid Immunoassay
9.4. Molecular
9.4.1. Isothermal Amplification
9.4.1.1. LAMP
9.4.1.2. RPA
9.4.2. PCR
9.4.2.1. Multiplex PCR
9.4.2.2. Real Time PCR
9.5. Rapid Test
9.5.1. Dipstick
9.5.2. Lateral Flow Assay
10. Sexually Transmitted Infection Diagnostics Kit Market, by Sample Type
10.1. Introduction
10.2. Blood
10.2.1. Serum
10.2.2. Whole Blood
10.3. Swab
10.3.1. Endocervical Swab
10.3.2. Rectal Swab
10.3.3. Urethral Swab
10.3.4. Vaginal Swab
10.4. Urine
10.4.1. First Catch Urine
10.4.2. Midstream Urine
11. Sexually Transmitted Infection Diagnostics Kit Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Diagnostic Laboratories
11.4. Hospitals
11.5. Research Institutes
12. Sexually Transmitted Infection Diagnostics Kit Market, by Distribution Channel
12.1. Introduction
12.2. Direct Tender
12.3. Hospital Pharmacy
12.4. Online Sales
12.5. Retail Pharmacy
13. Sexually Transmitted Infection Diagnostics Kit Market, by Application
13.1. Introduction
13.2. Confirmation
13.3. Monitoring
13.4. Screening
14. Americas Sexually Transmitted Infection Diagnostics Kit Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Sexually Transmitted Infection Diagnostics Kit Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Sexually Transmitted Infection Diagnostics Kit Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. F. Hoffmann-La Roche Ltd.
17.3.2. Abbott Laboratories
17.3.3. Becton, Dickinson and Company
17.3.4. Hologic, Inc.
17.3.5. Danaher Corporation
17.3.6. Thermo Fisher Scientific, Inc.
17.3.7. bioMérieux SA
17.3.8. Siemens Healthineers AG
17.3.9. Quidel Corporation
17.3.10. QIAGEN N.V.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET MULTI-CURRENCY
FIGURE 2. SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET MULTI-LANGUAGE
FIGURE 3. SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY INFECTION TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY INFECTION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 18. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY CHLAMYDIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY GONORRHEA, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY HIV, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SYPHILIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY CLIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY ELISA, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY RAPID IMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY MOLECULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY LAMP, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY RPA, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY PCR, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY MULTIPLEX PCR, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY RAPID TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY DIPSTICK, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY RAPID TEST, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY BLOOD, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SERUM, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SWAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY ENDOCERVICAL SWAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY RECTAL SWAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY URETHRAL SWAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY VAGINAL SWAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SWAB, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY URINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY FIRST CATCH URINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY MIDSTREAM URINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY DIRECT TENDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY ONLINE SALES, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY CONFIRMATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY MONITORING, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SCREENING, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY RAPID TEST, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SWAB, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY RAPID TEST, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SWAB, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 91. CANADA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 92. CANADA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 93. CANADA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 94. CANADA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 95. CANADA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2030 (USD MILLION)
TABLE 96. CANADA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 97. CANADA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY RAPID TEST, 2018-2030 (USD MILLION)
TABLE 98. CANADA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 99. CANADA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 100. CANADA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SWAB, 2018-2030 (USD MILLION)
TABLE 101. CANADA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 102. CANADA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 103. CANADA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 104. CANADA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 105. MEXICO SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 106. MEXICO SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 107. MEXICO SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 108. MEXICO SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 109. MEXICO SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2030 (USD MILLION)
TABLE 110. MEXICO SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 111. MEXICO SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY RAPID TEST, 2018-2030 (USD MILLION)
TABLE 112. MEXICO SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 113. MEXICO SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 114. MEXICO SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SWAB, 2018-2030 (USD MILLION)
TABLE 115. MEXICO SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 116. MEXICO SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. MEXICO SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. MEXICO SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY RAPID TEST, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SWAB, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 130. BRAZIL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 131. BRAZIL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 132. BRAZIL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 134. ARGENTINA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 135. ARGENTINA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 136. ARGENTINA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 137. ARGENTINA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2030 (USD MILLION)
TABLE 138. ARGENTINA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 139. ARGENTINA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY RAPID TEST, 2018-2030 (USD MILLION)
TABLE 140. ARGENTINA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 141. ARGENTINA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 142. ARGENTINA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SWAB, 2018-2030 (USD MILLION)
TABLE 143. ARGENTINA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 144. ARGENTINA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 145. ARGENTINA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 146. ARGENTINA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY RAPID TEST, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SWAB, 2018-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 162. UNITED KINGDOM SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 163. UNITED KINGDOM SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 164. UNITED KINGDOM SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 166. UNITED KINGDOM SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2030 (USD MILLION)
TABLE 167. UNITED KINGDOM SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 168. UNITED KINGDOM SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY RAPID TEST, 2018-2030 (USD MILLION)
TABLE 169. UNITED KINGDOM SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 170. UNITED KINGDOM SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 171. UNITED KINGDOM SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SWAB, 2018-2030 (USD MILLION)
TABLE 172. UNITED KINGDOM SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 173. UNITED KINGDOM SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 174. UNITED KINGDOM SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 175. UNITED KINGDOM SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 176. GERMANY SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 177. GERMANY SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 178. GERMANY SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 179. GERMANY SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 180. GERMANY SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2030 (USD MILLION)
TABLE 181. GERMANY SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 182. GERMANY SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY RAPID TEST, 2018-2030 (USD MILLION)
TABLE 183. GERMANY SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 184. GERMANY SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 185. GERMANY SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SWAB, 2018-2030 (USD MILLION)
TABLE 186. GERMANY SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 187. GERMANY SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 188. GERMANY SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 189. GERMANY SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 190. FRANCE SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 191. FRANCE SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 192. FRANCE SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 193. FRANCE SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 194. FRANCE SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2030 (USD MILLION)
TABLE 195. FRANCE SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 196. FRANCE SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY RAPID TEST, 2018-2030 (USD MILLION)
TABLE 197. FRANCE SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 198. FRANCE SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 199. FRANCE SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SWAB, 2018-2030 (USD MILLION)
TABLE 200. FRANCE SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 201. FRANCE SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 202. FRANCE SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 203. FRANCE SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 204. RUSSIA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 205. RUSSIA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 206. RUSSIA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 207. RUSSIA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 208. RUSSIA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2030 (USD MILLION)
TABLE 209. RUSSIA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 210. RUSSIA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY RAPID TEST, 2018-2030 (USD MILLION)
TABLE 211. RUSSIA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 212. RUSSIA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 213. RUSSIA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SWAB, 2018-2030 (USD MILLION)
TABLE 214. RUSSIA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 215. RUSSIA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 216. RUSSIA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 217. RUSSIA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 218. ITALY SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 219. ITALY SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 220. ITALY SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 221. ITALY SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 222. ITALY SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2030 (USD MILLION)
TABLE 223. ITALY SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 224. ITALY SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY RAPID TEST, 2018-2030 (USD MILLION)
TABLE 225. ITALY SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 226. ITALY SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 227. ITALY SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SWAB, 2018-2030 (USD MILLION)
TABLE 228. ITALY SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 229. ITALY SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 230. ITALY SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 231. ITALY SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 232. SPAIN SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 233. SPAIN SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 234. SPAIN SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 235. SPAIN SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 236. SPAIN SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2030 (USD MILLION)
TABLE 237. SPAIN SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 238. SPAIN SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY RAPID TEST, 2018-2030 (USD MILLION)
TABLE 239. SPAIN SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 240. SPAIN SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 241. SPAIN SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SWAB, 2018-2030 (USD MILLION)
TABLE 242. SPAIN SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 243. SPAIN SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 244. SPAIN SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 245. SPAIN SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 246. UNITED ARAB EMIRATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 247. UNITED ARAB EMIRATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 248. UNITED ARAB EMIRATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 249. UNITED ARAB EMIRATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 250. UNITED ARAB EMIRATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2030 (USD MILLION)
TABLE 251. UNITED ARAB EMIRATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 252. UNITED ARAB EMIRATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY RAPID TEST, 2018-2030 (USD MILLION)
TABLE 253. UNITED ARAB EMIRATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 254. UNITED ARAB EMIRATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 255. UNITED ARAB EMIRATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SWAB, 2018-2030 (USD MILLION)
TABLE 256. UNITED ARAB EMIRATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY URINE, 2018-2030 (USD MILLION)
TABLE 257. UNITED ARAB EMIRATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 258. UNITED ARAB EMIRATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 259. UNITED ARAB EMIRATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 260. SAUDI ARABIA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 261. SAUDI ARABIA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 262. SAUDI ARABIA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 263. SAUDI ARABIA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
TABLE 264. SAUDI ARABIA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2030 (USD MILLION)
TABLE 265. SAUDI ARABIA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 266. SAUDI ARABIA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY RAPID TEST, 2018-2030 (USD MILLION)
TABLE 267. SAUDI ARABIA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 268. SAUDI ARABIA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 269. SAUDI ARABIA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SWAB, 2018-2030 (USD MILLION)
TABLE 270. SAUDI ARABIA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY URINE, 201

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Sexually Transmitted Infection Diagnostics Kit market report include:
  • F. Hoffmann-La Roche Ltd.
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Hologic, Inc.
  • Danaher Corporation
  • Thermo Fisher Scientific, Inc.
  • bioMérieux SA
  • Siemens Healthineers AG
  • Quidel Corporation
  • QIAGEN N.V.

Related Topics

Related Reports

Sexually Transmitted Infections (STIs) Market Report 2025 - Product Image

Sexually Transmitted Infections (STIs) Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Sexually Transmitted Diseases (STD) Treatment Market 2024-2028 - Product Image

Sexually Transmitted Diseases (STD) Treatment Market 2024-2028

  • Report
  • 145 Pages
  • Global
From
2024-2029 Global Sexually-Transmitted Diseases (STD) Market: US, Europe, Japan - Supplier Shares and Sales Segment Forecasts by Test, Competitive Intelligence, Emerging Technologies, Instrumentation and Opportunities - Product Image

2024-2029 Global Sexually-Transmitted Diseases (STD) Market: US, Europe, Japan - Supplier Shares and Sales Segment Forecasts by Test, Competitive Intelligence, Emerging Technologies, Instrumentation and Opportunities

  • Report
  • Europe, Global, Japan, ... Europe, Global, Japan, United States
From
2025 Global Sexually-Transmitted Disease (STD) Market (US, Europe, Japan): Shares and Segment Forecasts-AIDS/HIV, Chancroid, Chlamydia, Gonorrhea, Granuloma Inguinale, Herpes I/II, Lymphogranuloma, Mycoplasma, Papillomavirus, Syphilis, Trichomonas Vaginalis - Product Image

2025 Global Sexually-Transmitted Disease (STD) Market (US, Europe, Japan): Shares and Segment Forecasts-AIDS/HIV, Chancroid, Chlamydia, Gonorrhea, Granuloma Inguinale, Herpes I/II, Lymphogranuloma, Mycoplasma, Papillomavirus, Syphilis, Trichomonas Vaginalis

  • Report
  • Global
From
Sexually Transmitted Disease Diagnostics Market by Diagnostic Test Types, Pathogen Types, End-User Types, Sample Types, Technology Types, Product Types - Global Forecast to 2030 - Product Image

Sexually Transmitted Disease Diagnostics Market by Diagnostic Test Types, Pathogen Types, End-User Types, Sample Types, Technology Types, Product Types - Global Forecast to 2030

  • Report
  • 184 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.